Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01087333 · ClinicalTrials.gov registry record
Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment
A clinical trial of Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkins Lymphoma (NHL), sponsored by National Cancer Institute (NCI).
- Recruiting
- Registry status
- 1,263
- Enrollment target
- 1
- Study location
NCT01087333: Recruiting study of Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkins Lymphoma (NHL), sponsored by National Cancer Institute (NCI).
NCT01087333 is a study of Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkins Lymphoma (NHL) that is actively recruiting participants, run by National Cancer Institute (NCI). The registered enrollment target is 1,263 participants, above the 148-participant average among 29 other Chronic Lymphocytic Leukemia (CLL) trials with a reported enrollment target (753% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01087333, a study of Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkins Lymphoma (NHL), is actively recruiting participants, sponsored by National Cancer Institute (NCI).
- RECRUITING
- Registry status
- 1,263 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: \- Researchers who are studying hairy cell leukemia, and how the disease compares with other disorders, are interested in obtaining additional samples from leukemia patients and healthy volunteers. The investigators are particularly interested in samples from individuals who have diseases that can be treated with a new type of drug called immunotoxin, in which an antibody carrying a toxin binds to a cancer cell and allows the toxin to kill the cell. Objectives: \- To collect a variety of clinical samples, including blood, urine, lymph samples, and other tissues, in order to study the samples and develop new treatments for leukemia. Eligibility: \- Individuals 18 years of age and older who have been diagnosed with leukemia or other kinds of blood and lymphatic system cancers, or who are healthy volunteers. Design: * Individuals who have leukemia will be asked to provide blood, bone marrow, urine, and tumor tissue samples as requested by the researchers. Healthy volunteers will provide only blood and urine samples. * No treatment will be given as part of this protocol.
Primary Outcome
Collection of a variety of clinical samples, including blood, urine, lymphapheresis samples, and other tissues and associated data
Conditions Studied
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,263 participants |
| Start Date | 2010-03-02 |
What NCT01087333 shows while recruiting
NCT01087333 is an observational study that tracks outcomes without assigning an intervention. Its 1,263 participants enrollment target places it among the larger protocols in the corpus, above the 148-participant average among 29 other Chronic Lymphocytic Leukemia (CLL) trials with a reported enrollment target (753% higher).
The record links to 5 conditions, with Chronic Lymphocytic Leukemia (CLL) appearing as the primary indexed condition, and to 0 interventions.
NCT01087333 reports a single indexed study location in Maryland.
Frequently Asked Questions
What is clinical trial NCT01087333 about?
NCT01087333 is a clinical study titled "Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment". Background: \- Researchers who are studying hairy cell leukemia, and how the disease compares with other disorders, are interested in obtaining additional samples from leukemia patients and healthy volunteers. The investigators are particularly interested in samples from individuals who have diseas...
What is the current status of trial NCT01087333?
This trial is currently recruiting. The enrollment target is 1,263 participants. The study started on 2010-03-02.
What conditions does trial NCT01087333 study?
This clinical trial studies the following conditions: Chronic Lymphocytic Leukemia (CLL), Non-Hodgkins Lymphoma (NHL), Cutaneous T Cell Lymphoma (CTCL), Hairy Cell Leukemia (HCL), Adult T Cell Lymphoma (ATL).
Who is sponsoring clinical trial NCT01087333?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01087333 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Lymphocytic Leukemia (CLL)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01087333's enrollment target sits among peer trials
1,263 2nd of 29 the highest of 29 other Chronic Lymphocytic Leukemia (CLL) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Lymphocytic Leukemia (CLL) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)
RECRUITING · Phase 2
-
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
RECRUITING · Phase 1
-
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
RECRUITING · Phase 1
-
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
RECRUITING · Phase 1
-
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
RECRUITING · Phase 2
-
Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06119581 · 1,264 participants · Phase 3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
- NCT06712316 · 1,260 participants · Phase 2
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
- NCT06812273 · 1,260 participants · NA
Mediators and Moderators of Auditory Training
- NCT06931340 · 1,260 participants · Phase 3
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI